You are here: Industry Insights > Magenta

News List

Magenta slips after FDA hold on early-stage trial of MGTA-117 in AML, MDS firstwordpharma
July 22, 2021
Magenta Therapeutics said Wednesday that it has received an FDA clinical hold letter regarding the investigational new drug application it filed in June to start a Phase I/II trial of MGTA-117 in patients with acute myeloid leukaemia (AML) and myelodyspla
Moderna and Magenta Partner to Distribute Moderna’s COVID-19 Vaccine and Boosters in United Arab Emirates americanpharmaceuticalreview
June 18, 2021
Moderna Inc. and Magenta Investments, a leading pharmaceutical and healthcare company based in the United Arab Emirates (UAE), announced a new agreement to distribute the Moderna COVID-19 Vaccine as well as Moderna’s updated variant booster candidates ...
Magenta, AVROBIO to evaluate antibody drug conjugate MGTA-117 pharmaceutical-technology
May 08, 2020
Magenta Therapeutics has signed an agreement with AVROBIO to evaluate the potential utility of its novel targeted antibody-drug conjugate (ADC) MGTA-117 as a potential conditioning regimen for lentiviral gene therapies.
Aptinyx, Magenta lead biotech IPO flurry ahead of summer lull fiercebiotech
June 25, 2018
No fewer than five biotech IPOs debuted Thursday, raising more than $460 million and with more in the offing if underwriters take up further options.
Magenta eyes $100M IPO to help ‘lead a new era in transplant medicine’ biospectrumasia
May 28, 2018
Coming off the back of a healthy financing round just six weeks ago, stem cell biotech Magenta Therapeutics now wants more, and it wants to go public.